Taiki Hakozaki1,2, Yusuke Okuma3,4, Kana Hashimoto1, Yukio Hosomi1. 1. Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan. 2. Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo, Tokyo, 105-0045, Japan. 3. Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan. yokuma@ncc.go.jp. 4. Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo, Tokyo, 105-0045, Japan. yokuma@ncc.go.jp.
Abstract
PURPOSE: Previously, the combination of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and bevacizumab (BEV) was investigated. A subgroup analysis of the IMpower150 trial, which investigated the combination of atezolizumab, carboplatin, paclitaxel, and bevacizumab (ABCP), demonstrated the benefit of ABCP in patients harboring EGFR mutations. This study aims to assess the prognostic significance of the qualification for BEV use and the proportion of patients who potentially benefit from BEV-containing combination therapy before and after initial EGFR-TKI treatment. METHODS: We retrospectively analyzed the data of 297 patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) harboring EGFR mutations who had received EGFR-TKIs. We performed statistical analyses using the Kaplan-Meier method and the Cox regression adjusted for risk factors. RESULTS: Of the 297 patients, 203 (68%) were eligible to receive BEV ("BEV fit") at the time of EGFR-TKI initiation. Among the "BEV unfit" patients at baseline (n = 70), 14 (20%) became eligible to receive ABCP ("ABCP fit") at the time of EGFR-TKI failure. The median overall survival (OS) of the "BEV fit" and "BEV unfit" patients was 26.2 [95% confidence interval (CI) 23.7-31.2] and 19.1 (95% CI 15.0-25.1) months, respectively (P < 0.001). The multivariate analysis revealed a marked correlation between survival and the qualification for BEV use. CONCLUSIONS: The qualification for BEV use at baseline is independently related to the OS. Some patients harboring EGFR mutations, including those who were "BEV unfit" at baseline, could be eligible for the ABCP regimen after EGFR-TKI treatment.
PURPOSE: Previously, the combination of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and bevacizumab (BEV) was investigated. A subgroup analysis of the IMpower150 trial, which investigated the combination of atezolizumab, carboplatin, paclitaxel, and bevacizumab (ABCP), demonstrated the benefit of ABCP in patients harboring EGFR mutations. This study aims to assess the prognostic significance of the qualification for BEV use and the proportion of patients who potentially benefit from BEV-containing combination therapy before and after initial EGFR-TKI treatment. METHODS: We retrospectively analyzed the data of 297 patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) harboring EGFR mutations who had received EGFR-TKIs. We performed statistical analyses using the Kaplan-Meier method and the Cox regression adjusted for risk factors. RESULTS: Of the 297 patients, 203 (68%) were eligible to receive BEV ("BEV fit") at the time of EGFR-TKI initiation. Among the "BEV unfit" patients at baseline (n = 70), 14 (20%) became eligible to receive ABCP ("ABCP fit") at the time of EGFR-TKI failure. The median overall survival (OS) of the "BEV fit" and "BEV unfit" patients was 26.2 [95% confidence interval (CI) 23.7-31.2] and 19.1 (95% CI 15.0-25.1) months, respectively (P < 0.001). The multivariate analysis revealed a marked correlation between survival and the qualification for BEV use. CONCLUSIONS: The qualification for BEV use at baseline is independently related to the OS. Some patients harboring EGFR mutations, including those who were "BEV unfit" at baseline, could be eligible for the ABCP regimen after EGFR-TKI treatment.
Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: F Ciardiello; R Bianco; V Damiano; G Fontanini; R Caputo; G Pomatico; S De Placido; A R Bianco; J Mendelsohn; G Tortora Journal: Clin Cancer Res Date: 2000-09 Impact factor: 12.531
Authors: C J Bruns; C C Solorzano; M T Harbison; S Ozawa; R Tsan; D Fan; J Abbruzzese; P Traxler; E Buchdunger; R Radinsky; I J Fidler Journal: Cancer Res Date: 2000-06-01 Impact factor: 12.701
Authors: A-M C Dingemans; A J de Langen; V van den Boogaart; J T Marcus; W H Backes; H T G M Scholtens; H van Tinteren; O S Hoekstra; J Pruim; B Brans; F B Thunnissen; E F Smit; H J M Groen Journal: Ann Oncol Date: 2010-08-11 Impact factor: 32.976
Authors: Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack Journal: J Thorac Oncol Date: 2016-01 Impact factor: 15.609
Authors: Ni Jun; Wang Hanping; Si Xiaoyan; Xu Yan; Wang Mengzhao; Zhang Xiaotong; Zhang Li Journal: Thorac Cancer Date: 2020-05-14 Impact factor: 3.500
Authors: Alain Vergnenègre; Victor Basse; Gwenaelle Le Garff; Olivier Bylicki; Catherine Dubos-Arvis; Bénédicte Comet; Marie Marcq; Jacques Le Treut; Jean-Bernard Auliac; Anne Madroszyk; Gislaine Fraboulet; Jacky Crequit; Pascal Thomas; Nicolas Paleiron; Isabelle Monnet Journal: Cancer Manag Res Date: 2019-12-27 Impact factor: 3.989